Network origin in Diane Mellett first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 26 | |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.
13
| Subsidiary | Biotechnology | 13 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Diane Mellett via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Chairman Founder | |
| University of Cambridge | College/University | Doctorate Degree Undergraduate Degree Masters Business Admin | |
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| BTG | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of London | College/University | Doctorate Degree Undergraduate Degree | |
| University of Glasgow | College/University | Doctorate Degree Graduate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| Faculty of Pharmaceutical Medicine | Director/Board Member Corporate Officer/Principal | ||
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| University of Oslo | College/University | Graduate Degree Doctorate Degree | |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Chairman Chairman | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
Healthcap 1999 GP AB
 Healthcap 1999 GP AB Investment Banks/BrokersFinance Part of Odlander, Fredrikson & Co. AB, Healthcap 1999 GP AB is a company that manages and trades securities. The company is based in Stockholm, Sweden. | Investment Banks/Brokers | Director/Board Member Director/Board Member | |
Healthcap Orx Holdings Gp AB
 Healthcap Orx Holdings Gp AB Investment Banks/BrokersFinance Healthcap Orx Holdings Gp AB is a private company that manages securities. The company is based in Stockholm, Sweden. | Investment Banks/Brokers | Director/Board Member Director/Board Member | |
| Healthcap Aero Holdings Gp | Director/Board Member Director/Board Member | ||
Ancilla AB
 Ancilla AB Real Estate DevelopmentFinance Ancilla AB manages real properties. The company is headquartered in Stockholm, Sweden. | Real Estate Development | Director/Board Member Director/Board Member | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Bayer AS
 Bayer AS Pharmaceuticals: MajorHealth Technology Bayer AS trades pharmaceutical products. It also provides animal health, crop science, and consumer health. The company was founded in 1964 and is headquartered in Lysaker, Norway. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Odlander, Fredrikson & Co. AB
 Odlander, Fredrikson & Co. AB Financial ConglomeratesFinance Odlander Fredrikson & Co. AB provides financial support services. The company was founded in 1996 and is headquartered in Stockholm, Sweden. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
ApaTech Ltd.
 ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Medical Specialties | Chairman Human Resources Officer | |
| University of Aarhus | College/University | Doctorate Degree Doctorate Degree | |
Pepgen Ltd.
 Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Packaged Software | Chairman | |
Mylan, Inc.
 Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| CANTARGIA AB | Pharmaceuticals: Major | Director/Board Member | |
Cytoseek Ltd.
 Cytoseek Ltd. Miscellaneous Commercial ServicesCommercial Services Cytoseek Ltd. provides cell membrane augmentation technology for enhancement of cell therapies for cancer, heart disease, osteoarthritis, and diabetic wound healing. It enables new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. The company was founded by Adam Willis Perriman on November 22, 2017 and is headquartered in Bristol, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
| Treehill Partners, LLC | Corporate Officer/Principal | ||
Imophoron Ltd.
 Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | Biotechnology | Chairman | |
Haemostatix Ltd.
 Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Operating Officer | |
Resolys Bio, Inc.
 Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Resolys Bio, Inc. operates as a pharmaceutical company. The firm develops OSLO and MCC for the treatment of certain forms of traumatic brain injury and chronic painful tissue disorders. The company is headquartered in Delanson, NY. | Miscellaneous Commercial Services | Director/Board Member | |
| Theralpha | Director/Board Member | ||
Agalimmune Ltd.
 Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Part of BioLineRx Ltd., Agalimmune Ltd. is a British company that develops anti-cancer immunotherapy technology. The company is based in London, UK. The company was founded by Charles Campbell Roberts and Graham Griffiths. The CEO is Mike Westby. Agalimmune was acquired by BioLineRx Ltd. on March 23, 2017 for $6.05 million. | Pharmaceuticals: Major | Director/Board Member | |
Loxbridge Research LLP
 Loxbridge Research LLP Financial ConglomeratesFinance Loxbridge Research LLP operates as an investment and project management company. It specializes in startup, early stage, and later stage investments in growth stage companies. The firm supports scientists and focuses on sectors like science, medicine and healthcare technology particularly biotech, med-tech, noval therapeutic, diagnostics, cancer, infectious diseases, neurodegeneration, imaging hardware and software, and enabling devices. The company was founded by Charles Roberts in 2008 and is headquartered in London, the United Kingdom. | Financial Conglomerates | Director/Board Member | |
| University of Leiden | College/University | Doctorate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Sales & Marketing |
Statistics
International
| United Kingdom | 16 |
| Sweden | 11 |
| United States | 7 |
| Norway | 6 |
| Denmark | 4 |
Sectoral
| Health Technology | 25 |
| Consumer Services | 9 |
| Finance | 9 |
| Technology Services | 3 |
| Commercial Services | 3 |
Operational
| Director/Board Member | 195 |
| Corporate Officer/Principal | 99 |
| Chairman | 75 |
| Independent Dir/Board Member | 44 |
| Chief Executive Officer | 35 |
Most connected contacts
| Insiders | |
|---|---|
| Thomas Falck | 62 |
| Per Anders Göte Samuelsson | 36 |
| Johan Rutger Christenson | 35 |
| Patrick Volkert Vink | 30 |
| David Chiswell | 23 |
| Peter Chambré | 23 |
| Damian Marron | 23 |
| Lars Lund-Roland | 19 |
| Peter Ringrose | 19 |
| Robert Forbes Burns | 16 |
| Hamish Alan Cameron | 14 |
| Sonia Quaratino | 13 |
| John Stocker | 12 |
| John Aston | 12 |
| Gunnar Gårdemyr | 11 |
- Stock Market
- Insiders
- Diane Mellett
- Company connections
